Abstract
Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa and fibrinogen GPIIb/IIIa binding (both in the micromolar range). These compounds resulted from our efforts to merge the pharmacophores of selective factor Xa inhibitor rivaroxaban with a mimic of the Arg-Gly-Asp (RGD) sequence of fibrinogen to obtain designed multiple ligands with potential antithrombotic activity. Resulting from this study, a structurally novel class of submicromolar fibrinogen GPIIb/IIIa binding inhibitor bearing 1,2,4-oxadiazol-5(4H)-one moiety is also described.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Dose-Response Relationship, Drug
-
Factor Xa / chemistry
-
Factor Xa Inhibitors*
-
Fibrinogen / antagonists & inhibitors*
-
Fibrinogen / chemistry
-
Humans
-
Models, Molecular
-
Molecular Structure
-
Molecular Weight
-
Oxadiazoles / chemical synthesis
-
Oxadiazoles / chemistry
-
Oxadiazoles / pharmacology*
-
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
-
Platelet Glycoprotein GPIIb-IIIa Complex / chemistry
-
Protein Binding / drug effects
-
Serine Proteases / metabolism
-
Serine Proteinase Inhibitors / chemical synthesis
-
Serine Proteinase Inhibitors / chemistry
-
Serine Proteinase Inhibitors / pharmacology*
-
Structure-Activity Relationship
Substances
-
Factor Xa Inhibitors
-
Oxadiazoles
-
Platelet Glycoprotein GPIIb-IIIa Complex
-
Serine Proteinase Inhibitors
-
Fibrinogen
-
Serine Proteases
-
Factor Xa